-
15190-5A selective agonist of S1P3 (EC<sub>50</sub> = 72-132 nM) less effectively activates S1P1 (EC<sub>50</sub> = 28-38 µM) and is ineffective at S1P2, S1P4, and S1P5 as well as a panel of other receptors, ion channels and transporters.
-
15190-50A selective agonist of S1P3 (EC<sub>50</sub> = 72-132 nM) less effectively activates S1P1 (EC<sub>50</sub> = 28-38 µM) and is ineffective at S1P2, S1P4, and S1P5 as well as a panel of other receptors, ion channels and transporters.
-
10009660-1CYPMPO is a free radical spin trap with excellent trapping capabilities toward hydroxyl and superoxide radicals in biological and chemical systems. Decay of the superoxide adduct of CYPMPO proceeds in an apparent first order fashion with half-lives
-
10009660-10CYPMPO is a free radical spin trap with excellent trapping capabilities toward hydroxyl and superoxide radicals in biological and chemical systems. Decay of the superoxide adduct of CYPMPO proceeds in an apparent first order fashion with half-lives
-
10009660-5CYPMPO is a free radical spin trap with excellent trapping capabilities toward hydroxyl and superoxide radicals in biological and chemical systems. Decay of the superoxide adduct of CYPMPO proceeds in an apparent first order fashion with half-lives
-
15614-10A positive modulator of the small conductance calcium-activated potassium channels SK2 and SK3 (EC<sub>50</sub>s = 14 and 5.6 µM, respectively) inactive on both SK1 and IK increases the apparent calcium-sensitivity of channel activation of
-
15614-50A positive modulator of the small conductance calcium-activated potassium channels SK2 and SK3 (EC<sub>50</sub>s = 14 and 5.6 µM, respectively) inactive on both SK1 and IK increases the apparent calcium-sensitivity of channel activation of
-
19551-1A first-generation antihistamine that potently antagonizes the histamine H1 receptor (pKi = 9.42) also antagonizes serotonin and muscarinic receptors at nanomolar concentrations.
-
19551-500A first-generation antihistamine that potently antagonizes the histamine H1 receptor (pKi = 9.42) also antagonizes serotonin and muscarinic receptors at nanomolar concentrations.
-
16622-1An antagonist/partial agonist of the androgen receptor (IC<sub>50</sub> = 26 nM in humans) that has been shown to have clinical use in androgen-dependent conditions such as prostate cancer, hirsutism, and alopecia suppresses accessory sexual glands
-
16622-100An antagonist/partial agonist of the androgen receptor (IC<sub>50</sub> = 26 nM in humans) that has been shown to have clinical use in androgen-dependent conditions such as prostate cancer, hirsutism, and alopecia suppresses accessory sexual glands
-
16622-250An antagonist/partial agonist of the androgen receptor (IC<sub>50</sub> = 26 nM in humans) that has been shown to have clinical use in androgen-dependent conditions such as prostate cancer, hirsutism, and alopecia suppresses accessory sexual glands